{"id":66947,"date":"2022-10-18T13:03:30","date_gmt":"2022-10-18T11:03:30","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=66947"},"modified":"2026-06-11T16:18:38","modified_gmt":"2026-06-11T14:18:38","slug":"veeva-introduces-new-epro-application-for-faster-access-to-patient-data","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/veeva-introduces-new-epro-application-for-faster-access-to-patient-data\/","title":{"rendered":"Veeva Introduces New ePRO Application for <br class=\"hidden-xs\"> Faster Access to Patient Data"},"content":{"rendered":"<p align=\"center\"><em>Veeva ePRO simplifies the collection and exchange <br \/>of patient-reported outcomes in digital clinical trials<\/em><\/p>\n<p><strong>BARCELONA, Spain &#8211; 18 Oct. 2022 \u2014<\/strong> <a href=\"\/eu\/\">Veeva Systems<\/a> (NYSE: VEEV) today announced the availability of <a href=\"\/eu\/products\/veeva-ecoa\/\">Veeva eCOA<\/a>, a key advancement in patient-centric digital trials. The application makes it easier for patients to complete assessments on a mobile device or web browser and enables real-time data access for sponsors and clinical research sites. As part of a connected platform for clinical trials, study teams can use ePRO to exchange high-quality data across the clinical ecosystem for improved transparency and collaboration.<\/p>\n<p>According to research sites, the top challenges in patient retention include the time required to participate in a trial, repetitive information requests, and time spent entering data<sup>1<\/sup>. Veeva ePRO improves the patient experience by providing a modern, user-friendly application for completing Patient-Reported Outcomes (PRO). <\/p>\n<p>The application also helps streamline trial activities for sponsors and research sites. Sponsors can configure studies using survey and instrument libraries and push ePRO and schedule definitions to research sites. Research sites can then easily assign activities, automatically receive updates, and track patient progress without needing other systems or applications.<\/p>\n<p>\u201cVeeva ePRO is built to meet the needs of patients, sites, and sponsors, and is connected for end-to-end execution,\u201d said Tim Davis, vice president of strategy, MyVeeva for Patients at Veeva. \u201cWe are committed to partnering with customers to deliver modern digital applications that help the life sciences industry advance to patient-centric digital trials.\u201d<\/p>\n<p>Veeva ePRO is part of <a href=\"\/eu\/products\/vault-clinical\/\">Veeva Vault Clinical Suite<\/a>, the industry\u2019s first cloud platform that unifies clinical data management and operations. Vault Clinical Suite includes <a href=\"\/eu\/products\/vault-edc\/\">Vault EDC<\/a>, <a href=\"https:\/\/rtsm.veeva.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Veeva RTSM<\/a>, Veeva ePRO, <a href=\"\/eu\/products\/veeva-cdb\/\">Veeva CDB<\/a>, <a href=\"\/eu\/products\/vault-etmf\/\">Vault eTMF<\/a>, <a href=\"\/eu\/products\/vault-ctms\/\">Vault CTMS<\/a>, <a href=\"\/eu\/products\/veeva-site-connect\/\">Veeva Site Connect<\/a>, <a href=\"\/eu\/products\/vault-payments\/\">Vault Payments<\/a>, <a href=\"\/eu\/products\/vault-study-startup\/\">Vault Study Start-up<\/a>, and <a href=\"\/eu\/products\/vault-study-training\/\">Vault Study Training<\/a>. Learn more about Veeva ePRO at <a href=\"\/eu\/products\/veeva-ecoa\/\">veeva.com\/eu\/ecoa<\/a>.<\/p>\n<p><strong>Additional Information<\/strong><\/br><br \/>\nConnect with Veeva on LinkedIn: <a href=\"https:\/\/www.linkedin.com\/company\/veeva-systems\" target=\"_blank\" rel=\"noopener noreferrer\">linkedin.com\/company\/veeva-systems<\/a><br \/>\nFollow @veeva_eu on Twitter: <a href=\"https:\/\/www.twitter.com\/veeva_eu\" target=\"_blank\" rel=\"noopener noreferrer\">twitter.com\/veeva_eu<\/a><br \/> \n<\/p>\n<p><strong>About Veeva Systems<\/strong><br \/>\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href=\"\/eu\/\">veeva.com\/eu<\/a>.<\/p>\n<p><strong>Veeva Forward-looking Statements<\/strong><br \/>\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find <a href=\"https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1393052\/000139305222000036\/veev-20220731.htm\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a> (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at <a href=\"https:\/\/www.sec.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">sec.gov<\/a>.<\/p>\n<p>###<\/p>\n<p><strong>Contact:<\/strong><\/p>\n<p>Jeremy Whittaker<br \/>\nVeeva Systems<br \/>\n+49 6950955486<br \/>\n<a href=\"mailto:jeremy.whittaker@veeva.com\">jeremy.whittaker@veeva.com<\/a><\/p>\n<p>Deivis Mercado<br \/>\nVeeva Systems<br \/>\n925-226-8821<br \/>\n<a href=\"mailto:deivis.mercado@veeva.com\">deivis.mercado@veeva.com<\/a><\/p>\n<p>___________________________________<br \/>\n<sup>1. SCRS Research Report, <a href=\"https:\/\/myscrs.org\/uncategorized\/scrs-releases-research-report-on-the-impact-of-eclinical-technologies-and-related-initiatives-on-sites\/\" target=\"_blank\" rel=\"noopener noreferrer\">Impact Assessment of eClinical Technologies and Industry Initiatives on Sites<\/a>, 2019<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Veeva ePRO simplifies the collection and exchange of patient-reported outcomes in digital clinical trials.<\/p>\n","protected":false},"featured_media":67005,"parent":0,"template":"","class_list":["post-66947","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-html-content-yes","resource-area-20-clinical-operations","resource-area-20-vault-platform-area","resource-product-20-epro","resource-product-20-site-connect","resource-product-20-sponsor-site-collaboration","resource-product-20-vault-platform","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/66947"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":1,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/66947\/revisions"}],"predecessor-version":[{"id":67008,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/66947\/revisions\/67008"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/67005"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=66947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}